Modulation of Ocular Inflammation by Mesenchymal Stem Cells
Technical Report,24 Dec 2014,23 Dec 2016
Schepens Eye Research Institute Boston United States
Pagination or Media Count:
Ocular injury and inflammations are commonly treated with non-specific anti-inflammatory drugs such as corticosteroids. These non-specific treatments typically target both pathogenic and regulatory cells of the immune system, and are associated with side effects such as infection, cataract and glaucoma. Thus, there is a pressing need for new immunomodulatory strategies that not only inhibit pathogenic immune cells, but also promote critical regulatory immune cells that promote immune quiescence, such as myeloid-derived suppressor cells MDSC. Bone marrow-derived mesenchymal stem cells BM-MSC have shown promise in exerting immunomodulatory functions, and present a novel and potentially effective alternative to the current non-specific immunosuppressive therapies. The goal of this project is to investigate the mechanisms by which BM-MSC modulate maturation and differentiation of immature myeloid progenitor cells into MDSC away from pathogenic macrophages to control ocular inflammation. We anticipate that these investigations will identify critical immunomodulatory factors which may be used to design novel, targeted strategies for treating eye injury and inflammation.
- Medicine and Medical Research